

Datasheet for 009-001-B32**IL-17A Human Recombinant Protein****Overview**

Description:	IL-17A Human Recombinant Protein - 009-001-B32
Item No.:	009-001-B32
Size:	25 µg
Applications:	SDS-PAGE
Origin:	Human
Expressed in:	E. coli

Product Details

Background:	Interleukin17-A is a proinflammatory cytokine produced by activated T cells and exists as a homodimer. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. IL-17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. IL17-A is the founding member of a group of cytokines called the IL-17 family. IL17-A was originally identified as a transcript from a rodent T-cell hybridoma. To elicit its functions, IL17 binds to a type I cell surface receptor called IL17R of which there are at least three variants: IL17RA, IL17RB, and IL17RC.
Synonyms:	Interleukin-17 cytokine, IL-17, IL-17A, Interleukin-17A, Cytotoxic T-Lymphocyte-associated Antigen 8, CTLA8.
Species of Origin:	Human
Expressed in:	E. coli
Type:	Recombinant Protein
Low Endotoxin:	Yes

Target Details

Gene Name:	IL17A
-------------------	-------

Purity/Specificity: Recombinant protein corresponds to amino acids 19 - 155 of mature human IL-17A. Its molecular weight is 15,667 Daltons. Purity is greater than 90% as determined by reducing and non-reducing SDS-PAGE and by analytical HPLC.

Relevant Links:

- [UniProtKB - Q16552](#)
- [NCBI](#)

Application Details

Tested Applications: SDS-PAGE

Application Note: IL-17A protein has been tested by SDS-PAGE and is suitable as a control for polyclonal or monoclonal anti-IL-17A in immunological assays.

Assay Dilutions: All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Other: Biological Activity: Human IL-17A is fully biologically active when compared to standards via dose-dependent induction of IL-6 production in cultured mouse NIH 3T3 fibroblasts. The ED50 for recombinant human IL-17A in this assay was 1.4-2.1 ng/mL.

Endotoxin Level: Measured by LAL is <0.01ng/μg or <0.1EU/μg.

Formulation

Physical State: Lyophilized

Concentration: 0.1 mg/mL by UV absorbance at 280 nm

Buffer: 0.1% Trifluoroacetic acid

Preservative: None

Stabilizer: None

Reconstitution Volume: 250 μL

Reconstitution Buffer: Restore with deionized water (or equivalent)


Shipping & Handling

Shipping Condition: Ambient

Storage Condition: Store vial at 4° C prior to restoration. Dilute only prior to immediate use. Maintain sterility. This product DOES NOT contain preservative. DO NOT VORTEX. We recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL) . For best results aliquot contents and freeze at -20° C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.

Expiration: Expiration date is six (6) months from date of receipt.

Images



SDS-PAGE

SDS-PAGE using Rockland's Recombinant Human IL-17A protein shows bands corresponding to IL-17A (1µg) in lane 1 (unreduced) and lane 3 (reduced). Molecular weight estimation was made by comparison to prestained MW markers, lane 2.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.